According to Research by SNS Insider, The U.S. GLP-1 Receptor Agonist Market to Reach USD 113.13 Billion by 2032, Driven by Rising Prevalence of Type 2 Diabetes and Demand for Obesity-Related ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Teladoc Health is launching a new employee assistance program (EAP) called Wellbound, which it said is designed to promote a ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Kiran Musunuru, a University of Pennsylvania cardiologist and leading gene-editing researcher, thinks it’s possible. Musunuru cofounded Verve Therapeutics, a company developing a therapy that uses ...